• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Palatin’s LeuTech begins phase III trials

Article

Biopharmaceutical firm Palatin Technologies of Princeton, NJ, announced that it will begin multisite phase III trials next month for LeuTech, its radiopharmaceutical for infection imaging. LeuTech consists of a monoclonal antibody labeled with technetium

Biopharmaceutical firm Palatin Technologies of Princeton, NJ, announced that it will begin multisite phase III trials next month for LeuTech, its radiopharmaceutical for infection imaging. LeuTech consists of a monoclonal antibody labeled with technetium for imaging such infections as appendicitis and osteomyelitis. Palatin expects to complete phase III trials in the first part of 1999.

The firm is also working on peptide-based therapeutics and imaging agents such as PT5, a cancer therapeutic; PT11, an infection imaging agent based on the company's metal ion-induced distinctive array of structures (MIDAS) metallopeptide technology; and PT14, a therapeutic agent for sexual dysfunction.

Related Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.